Karen Prange sells $905,000 in AtriCure stock

A director at AtriCure sold nearly $905,000 worth of company stock in a single transaction on August 5, according to an SEC filing. Karen Prange, a board member at the Ohio-based medical device maker, disposed of 23,325 shares at an average price of $38.80, reducing her total direct holdings in the company by 14%. The sale occurred through open market transactions, meaning Prange did not use the stock to cover taxes or other obligations.

The timing of the sale may ease concerns about insider selling. It came just two weeks after AtriCure reported strong second-quarter results, with revenue up 13% to $154 million and net income swinging to $9 million from a loss the prior year. The company also raised its full-year guidance, citing strong adoption of its cryoSPHERE MAX probe, which contributed to a 27% jump in its pain management franchise. Analysts note that directors often sell shares to diversify portfolios or fund personal needs, and Prange retained nearly 23,000 shares after the sale, suggesting this was a strategic trim rather than a full exit.

AtriCure specializes in cardiac surgical devices, including radiofrequency ablation technology used to treat heart arrhythmias. With a market capitalization of $2.0 billion and trailing twelve-month revenue of $569.6 million, the company has carved out a niche in a competitive medical device market. Its global distribution network spans multiple continents, and its recent profitability—after years of growing sales without consistent earnings—marks a significant milestone. CEO Michael Carrel called the quarter “solid,” and the company’s improved outlook reflects growing confidence in its growth strategy.

While insider transactions can raise eyebrows, this sale appears routine rather than alarming. Directors often adjust their holdings over time, especially after strong performance. For investors, the key takeaway is AtriCure’s ability to sustain revenue growth while turning profitable—a shift that could strengthen its long-term position. Still, as with any stock, diversification and careful timing matter. The company’s recent momentum may reassure shareholders, but market conditions and execution risks always remain.